Grade 1–4 adverse events of interest that occurred most frequently were fatigue (342 [69%] of 498 with standard of care plus abiraterone vs 272 [54%] of 502 with standard of care in the abiraterone trial and 382 [86%] of 445 with standard of care plus abiraterone and enzalutamide vs 309 [68%] of 454 with standard of care in the abiraterone and enzalutamide trial), hypertension (187 [37%] vs 64 [13%] and 256 [58%] vs 72 [15%]), and alanine aminotransferase or aspartate aminotransferase increase (or both; 136 [27%] vs 72 [14%] and 166 [37%] vs 83 [18%]; table 2; appendix pp 7–13, 23). The gene discussed is GPT; the disease is Hypertension.